In vitro analysis of combination of cytokines and inhibitors of immunosuppression on cancer cells
October 2017
IRCCS for Oncology, Genoa, Italy
Small Cell Lung Cancer (SCLC) is an aggressive tumor characterized by rapid and extensive metastatic dissemination, recurrence after chemotherapy and poor prognosis. Recently, immunotherapy with anti-PD-1 antibodies has shown clinical benefit in recurrent Small Cell Lung Cancer (SCLC). In the present study, the researchers aimed at better understanding the mechanism that promotes reactivation of anti-tumor Cytotoxic T Lymphocyte (CTL) responses. Human SCLC cell lines were treated in vitro with different cytokines together with anti-PD-1 and analysed by flow cytometry and quantitative measurements of RNA. One cytokine was characterized as having a specific capacity to enhance the effects of anti-PD-1 which should be exploited as a potential combinatorial therapeutic strategy.
IL-27 mediates HLA class I up-regulation, which can be inhibited by the IL-6 pathway, in HLA-deficient small cell lung cancer cells
Silvano Ferrini, Marina Fabbi
Added on: 09-15-2021
[1] https://jeccr.biomedcentral.com/articles/10.1186/s13046-017-0608-z[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
